Diabetes Risk and Health Policy Proposals Top Healthcare News

A look at the latest news in healthcare, including a study that identifies an increased risk of diabetes in cancer survivors, 2 FDA approvals, Senator Bernie Sanders released a plan for universal healthcare coverage in the US, and the economics of aging.

Related Videos

Related Content

Advertisement

May 21st 2025

Global Skin Cancer Burden Among Older Adults Surged Since 1990, Driven by Keratinocyte Cancer

Giuliana Grossi

New global analysis calls for urgent, targeted interventions as aging populations face rising rates of skin cancer.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

May 20th 2025

Is the US Headed for an Infectious Disease Pandemic?

Giuliana Grossi

In an era that FDA Commissioner Marty Makary, MD, MPH, calls an "epidemic of distrust" toward health institutions, previously contained disease rates are rapidly rising, and vaccination rates are proceeding in the opposite direction.

May 9th 2025

Frameworks for Advancing Health Equity: Food as Medicine

Giuliana Grossi Colleen Ereditario, MPH, RD, LDN

Learn about how Allegheny Health Network's "Food as Medicine" initiative tackles food insecurity and enhances health through personalized nutrition support.

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).

Related Content

Advertisement

May 21st 2025

Global Skin Cancer Burden Among Older Adults Surged Since 1990, Driven by Keratinocyte Cancer

Giuliana Grossi

New global analysis calls for urgent, targeted interventions as aging populations face rising rates of skin cancer.

May 13th 2025

Inside the Center's MDD Value Model and Its Use of Dynamic Pricing

Brooke McCormick Larragem Raines, MS

Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.

May 20th 2025

Is the US Headed for an Infectious Disease Pandemic?

Giuliana Grossi

In an era that FDA Commissioner Marty Makary, MD, MPH, calls an "epidemic of distrust" toward health institutions, previously contained disease rates are rapidly rising, and vaccination rates are proceeding in the opposite direction.

May 9th 2025

Frameworks for Advancing Health Equity: Food as Medicine

Giuliana Grossi Colleen Ereditario, MPH, RD, LDN

Learn about how Allegheny Health Network's "Food as Medicine" initiative tackles food insecurity and enhances health through personalized nutrition support.

May 17th 2025

The Role of Transplant in the Era of Novel MM Therapies: Harsh Parmar, MD

Laura Joszt, MA Harsh Parmar, MD

Novel therapies for multiple myeloma (MM), including chimeric antigen receptor T-cell and bispecific antibodies, extend lives but raise concerns about treatment costs and adherence, and they haven't replaced stem cell transplantation, Harsh Parmar, MD, of Hackensack University Medical Center, explains.

May 17th 2025

Lower Risk of Cardiovascular Events With Acalabrutinib vs Ibrutinib in CLL in Real-World Study

AJMC Contributor

The real-world data showed lower rates of atrial fibrillation and hypertension associated with the second-generation Bruton tyrosine kinase inhibitor among patients with chronic lymphocytic leukemia (CLL).